Researchers reported mechanistic cancer biology implicating NAT10 in both chemotherapy resistance and immune evasion in gastric cancer. The findings, published in Cell Death Discovery, describe how NAT10 can drive cisplatin resistance and facilitate escape from immune control, linking inflammatory and epigenetic or transcriptional regulation to treatment failure. The report positions NAT10 as a potential intervention point for improving response to cisplatin-based regimens and for designing strategies that reduce immune escape mechanisms that tumors develop during therapy. The work adds to the growing body of evidence that resistance phenotypes and immune modulatory pathways are intertwined, suggesting biomarker and target development could connect predictive assays to combination treatment selection.